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Kinase inhibitors are a major focus in drug development. Recent work
shows that subtle temperature changes in the physiologically relevant tem-
perature range can dramatically alter kinase activity and specificity. We
argue that temperature is an essential factor that should be considered in
inhibitor screening campaigns. In many cases, high-throughput screening is
performed at room temperature or 30 °C, which may lead to many false
positives and false negatives when evaluating potential inhibitors in the
physiological temperature range. As one example, we discuss a new anti-
malaria compound that inhibits the highly temperature-sensitive kinase
CLK3 (CDC2-like kinase 3) from Plasmodium falciparum.
Introduction
Pharmacological modulation of kinase activity using
small molecules has been a central endeavor in drug
development, in particular in the treatment of cancer
[1]. Countless targeted studies and high-throughput
screens in academia and industry have led to the iden-
tification of numerous inhibitors, some of which have
made their way into the clinic [2]. In many cases,
three-dimensional structures of target kinases in com-
plex with small molecule inhibitors have been solved
and used to chemically modify and improve inhibitors
[3]. However, recent work suggests an additional
dimension that has been neglected in previous screen-
ing campaigns and validations: the impact of tempera-
ture, more specifically body temperature. In fact,
common high-throughput screening platforms perform
a kinase reaction at room temperature or 30 °C (e.g.,
[4–6] also see http://www.kinase-screen.mrc.ac.uk/),
which is obviously below human body temperature,
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°C, degree Celsius; 32P-c-ATP, adenosine triphosphate, labeled on the gamma phosphate withnonbreakingspace32P; Anopheles spec.,
Anopheles species; CLK, CDC2-like kinases; CLK1, CDC2-like kinase 1; CLK3, CDC2-like kinase 3; Kd, kinase domain; MBP, myelin basic
protein; P. falciparum, Plasmodiumnonbreakingspacefalciparum; Pf, Plasmodiumnonbreakingspacefalciparum; Plasmodium spp., Plasmodium
species; SD, standard deviation; SR protein, serine/arginine-rich protein; SRPK, SR protein kinase; SRSF1, serine/arginine-rich splicing factor 1.
3148 The FEBS Journal 288 (2021) 3148–3153 ª 2020 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
that is, the environment where the inhibitor should
eventually be used. Here we suggest that this discrep-
ancy in temperature may contribute to false positives
and false negatives in high-throughput inhibitor
screens and argue that temperature is an important
variable that should be considered when screening for
and validating kinase inhibitors.
The molecular basis for kinase
temperature sensitivity
Recent work shows that the activity and/or specificity
of at least two kinase families, p38alpha and CDC2-
like kinases (CLKs), is highly responsive to tempera-
ture changes in the physiological temperature range
[7,8]. P38alpha belongs to the family of mitogen-acti-
vated kinases [9], whereas CLKs phosphorylate SR
proteins, a family of proteins that control pre-mRNA
processing, for example, alternative splicing [10].
Recent work has shown that circadian oscillations in
core body temperature of only 1–2 °C are sufficient to
control CLK activity, which then alters the phosphory-
lation state of SR proteins and globally controls alter-
native splicing and gene expression [11,12]. This
temperature-dependent change in CLK activity is
mediated through subtle and reversible structural
changes in the kinase activation segment, which in
addition to controlling kinase activity is also involved
in substrate binding and could thus alter substrate
specificity and inhibitor binding [8]. Available CLK
inhibitors have been identified in screens at 30 °C or
room temperature [13–16], whereas a screen at 37 °C
or 38 °C, which induces the alternative conformation,
has not been performed.
Similarly, a substrate-specific change in activity
between 33 °C and 39.5 °C has been reported for
p38alpha, which is caused by a temperature-dependent
conformational change, in this case in the substrate
binding domain, which alters the affinity for different
substrates [7]. Such structural rearrangements in close
proximity to the substrate and nucleotide binding site
switch these kinases on and off or change substrate
specificity in a temperature range between 34 °C and
38 °C and will obviously affect the binding of poten-
tial inhibitors. Interestingly, altered conformational
dynamics of the activation segment has been suggested
to contribute to the emergence of tumors that display
resistance to the kinase inhibitor imatinib through
altered inhibitor binding [17]. This provides strong evi-
dence that conformational dynamics of the activation
segment, which is temperature-dependent, can indeed
influence inhibitor binding. Screening at room temper-
ature will thus result in a different set of hits than
screening at 30 °C or 37 °C. This ambiguity will on
the one hand contribute to the low percentage of ini-
tial hits that also perform at physiological tempera-
tures at 37 °C. On the other hand, screening at room
temperature may result in false negatives, as there may
be promising candidates that only bind to the kinase
in the 37 °C conformation and that are thus scored
no inhibition at 
core
body temperature
false positive false negative
screen at 30 °C candidate testing
at 37 °C
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Fig. 1. Temperature-dependent conformational changes can influence the results of high-throughput screens. Model how temperature-
dependent conformational changes in kinases can lead to false positives (left) and false negatives (middle) when performing high-throughput
screening at room temperature or 30 °C; the right panel shows a temperature-dependent change in substrate specificity.
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negative at lower temperatures (Fig. 1). Notably, com-
paring inhibitor activity in vitro (between room tem-
perature and 30 °C) and in cell culture (at 37 °C)
revealed in several cases strong differences [18,19],
which is in line with the hypothesis discussed above. It
should also be noted that the recombinant kinases
used for inhibitor screens are in most cases expressed
in bacteria and thus may lack functionally important
post-translational modification. While this is a general
concern, the CLK and p38 proteins in the examples
discussed above were bacterially expressed and main-
tained temperature sensitivity, suggesting this trait to
be independent of additional modifications.
Plasmodium falciparum CLK3 and an
antimalaria compound as an example
Interestingly, CLKs from different organisms have
adapted to the physiologically relevant temperature
range of the respective species, from mammals to flies,
reptiles, and parasites ([8] and see below). We will dis-
cuss one example in detail, the CLK3 homolog from
Plasmodium falciparum, to highlight the importance of
considering temperature when screening for kinase
inhibitors. Malaria is one of the most frequent infec-
tious diseases, and, with more than 200 million new
infections and 405 000 deaths per year (WHO malaria
report 2019), represents a global health threat. There is
an urgent need to develop new antimalaria therapeu-
tics, especially due to developing resistance against con-
ventional treatments [20]. The disease is transmitted via
the mosquito Anopheles from which the protozoan par-
asite Plasmodium spp. is transferred into the human
host (reviewed in Ref. [21]). The parasite has a complex
life cycle and needs to undergo dramatic morphological
changes to adapt to the different hosts, which in turn
requires massive changes in gene expression. Some of
these changes appear to be mediated through alterna-
tive splicing, as, for example, the splicing regulatory
protein PfSR1, a homolog of human SR protein
SRSF1, is required for Plasmodium spp. proliferation
in human red blood cells [22–25]. Thus, alternative
splicing is increasingly recognized as potential point for
therapeutic intervention. Alternative splicing is globally
controlled through the phosphorylation status of SR
proteins, which are phosphorylated by two classes of
kinases, CLKs and SRPKs. In P. falciparum, the
importance of CLK3 (PfCLK3) has been highlighted
by the finding that it plays an essential role in main-
taining the asexual blood stage of the parasite [26]. In
recent work, Alam et al. [22] identified and validated a
potential new antimalaria drug that specifically inhibits
PfCLK3. A high-throughput screen (kinase reaction
performed at room temperature) revealed the com-
pound TCMDS-135051 as a highly selective and speci-
fic PfCLK3 kinase inhibitor. This was confirmed
in vivo by the finding that parasite strains that devel-
oped resistance against TCMDS-135051 acquired
mutations in PfCLK3. Gene expression analysis
showed that upon inhibitor treatment transcription was
impaired and intron-containing genes were overrepre-
sented in the downregulated genes, pointing to a poten-
tial connection of PfCLK3 and splicing, which,
however, was not further analyzed [22].
As mentioned above, the best-characterized sub-
strates of CLKs are SR proteins. To further elucidate
the role of PfCLKs in controlling SR protein phos-
phorylation, we used our established in vitro kinase
assay with an SR repeat as substrate. We have previ-
ously shown that the in vitro activity faithfully mimics
the activity of the respective kinase in living cells [8].
Our assays demonstrate that the activity of both,
PfCLK1 and PfCLK3, strongly responds to tempera-
ture changes in the physiologically relevant tempera-
ture range (Fig. 2). The temperature optima of both
kinases are around 22 °C and remarkably, both
kinases are basically inactive toward phosphorylating
an SR repeat at 37 °C. Interestingly the optimal tem-
perature for Anopheles populations is 20–26 °C [27],
which is also the optimal temperature for P. falci-
parum development and transmission to humans [28].
This temperature range will induce maximal CLK
activity, whereas the activity is switched off upon
transmission into the human host simply by the altered
temperature (Fig. 2). We hypothesize that P. falci-
parum uses the different host temperature leading to
altered CLK activity and SR protein phosphorylation
to induce the massive changes in gene expression
required in different life cycle stages, but this idea
awaits experimental validation.
The PfCLK temperature-response curve raises the
question, how TCMDS-135051 can be active as an
antimalaria compound, if its target, PfCLK3, is not
active when the parasite is in the human host. The
answer may lie in changed substrate specificity con-
ferred by higher temperature. Alam et al. [22] used
myelin basic protein (MBP) as in vitro substrate,
which is not an SR protein and may thus not be the
physiologically relevant substrate, but they clearly
observed phosphorylation by PfCLK3 at 37 °C. Fur-
thermore, autophosphorylation of PfCLK3 was still
weakly active at 37 °C (Fig. 2, also see Ref. [22]), sug-
gesting that higher temperature primarily affects the
phosphorylation of SR proteins but that other targets
may still be phosphorylated. This could point to a
temperature-dependent change in substrate selectivity.
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Interestingly, PfCLK3 autophosphorylation happens
at tyrosine 526 [26] and MBP has two predicted tyro-
sine phosphorylation sites and these substrates were
both phosphorylated at 37 °C. In contrast, an SR
repeat was not phosphorylated at 37 °C, pointing to a
temperature-dependent change in target amino acid
specificity. This could be controlled through confor-
mational changes of the activation segment, which
makes direct contact to the substrate and could thus
inhibit of favor binding of specific substrates. A simi-
lar phenomenon has been described for p38alpha,
where changes in the physiological temperature range
alter substrate affinity and specificity by subtle confor-
mational changes [7], suggesting this to be a general
phenomenon. Thus, while TCMDS-135051 is clearly
acting as an antimalaria agent, it may do so by
inhibiting the phosphorylation of noncanonical and as
of yet unknown targets with equally unknown func-
tionality.
Conclusion
Together these data emphasize that temperature
should be considered as an important variable in
kinase inhibitor screening campaigns, as even subtle
changes within the physiologically relevant tempera-
ture range can have a dramatic impact on kinase activ-
ity and substrate specificity. Furthermore, we
hypothesize that repeating screens at 37 °C will yield
new promising lead structures that were false negatives
in screening campaigns at lower temperature.
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Fig. 2. Kinase activity of PfCLK1 and PfCLK3 is temperature-dependent in the physiological relevant temperature range of the vector
Anopheles spec. (A) An in vitro kinase assay with bacterially expressed His-tagged PfCLK1 kinase domain (kd) and a GST-RS-peptide as
substrate. Kinase and substrate were incubated at the indicated temperatures with 32P-c-ATP as described in Ref. [6]. A representative gel
is shown. The top gel is the Coomassie stain after SDS/PAGE to confirm equal loading and the bottom gel the autoradiograph (32P) of the
same gel. (B) Quantification of substrate phosphorylation (red) relative to the highest activity (n = 3, mean  SD); autophosphorylation was
not detectable. (C) In vitro kinase assays with bacterially expressed His-tagged PfCLK3 full length performed as in (A). PfCLK3 degradation
products are marked with asterisks. (D) Quantification of substrate (orange) and autophosphorylation (black) relative to the highest activity
(n = 3, mean  SD).
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